81
IRUS TotalDownloads
Altmetric
Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study
File | Description | Size | Format | |
---|---|---|---|---|
![]() | Accepted version | 3.24 MB | Adobe PDF | View/Open |
Title: | Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study |
Authors: | Gyberg, V Kotseva, K Dallongeville, J De Backer, G Mellbin, L Ryden, L Wood, D De Bacquer, D |
Item Type: | Journal Article |
Abstract: | Purpose: The aim was to investigate the use of cardioprotective drug therapies (aspirin or other antiplatelet agents, β-blockade, renin-angiotensin-aldosterone-system-blockade (RAAS-blockade) and statins) and treatment targets achieved in a large cohort of patients with established coronary artery disease and diabetes across Europe. Methods and results: EUROASPIRE III is an observational cross-sectional study of stable coronary artery disease patients aged 18–80 years from 76 centres in 22 European countries conducted in 2006–2007. The glycaemic status (prevalent, incident or no diabetes), the guideline treatment targets achieved and the use of pharmacotherapies were assessed at one visit 6-36 months after the index event. Of all 6588 patients investigated (women 25%), 4295 (65%) had no diabetes, 752 (11%) had incident diabetes and 1541 (23%) had prevalent diabetes. All four drugs were used in 44% of the patients with no diabetes, 51% with incident diabetes and 50% with prevalent diabetes respectively. Individual prescriptions for patients with no, incident and prevalent diabetes were respectively: aspirin or other antiplatelet agents 91, 93, and 91%; β-blockers: 81, 84, and 79%; RAAS-blockers: 77, 76, and 68%; statins: 80, 80, and 79%. The proportion of patients with coronary artery disease and prevalent diabetes reaching the treatment targets were 20% for blood pressure, 53% for low density lipoprotein cholesterol (LDL-cholesterol) and 22% for haemoglobin A1c (HbA1c). Conclusion: This European study demonstrates a low use of cardioprotective drug therapies among patients with a combination of coronary artery disease and diabetes, which will be contributing to the poor achievement of risk factor treatment targets for cardiovascular prevention. |
Issue Date: | 1-Apr-2015 |
Date of Acceptance: | 4-Mar-2014 |
URI: | http://hdl.handle.net/10044/1/57448 |
DOI: | https://dx.doi.org/10.1177/2047487314529353 |
ISSN: | 2047-4873 |
Publisher: | SAGE Publications |
Start Page: | 753 |
End Page: | 761 |
Journal / Book Title: | European Journal of Preventive Cardiology |
Volume: | 22 |
Issue: | 6 |
Copyright Statement: | © The European Society of Cardiology 2014. Reprinted by permission of SAGE Publications. |
Keywords: | Science & Technology Life Sciences & Biomedicine Cardiac & Cardiovascular Systems Cardiovascular System & Cardiology Cardiovascular disease diabetes mellitus secondary prevention EUROASPIRE CARDIOVASCULAR-DISEASE EURO HEART MYOCARDIAL-INFARCTION GLUCOSE REGULATION RISK-FACTORS PREVENTION MANAGEMENT MORTALITY MELLITUS CARE Adolescent Adrenergic beta-Antagonists Adult Aged Aged, 80 and over Angiotensin II Type 1 Receptor Blockers Angiotensin-Converting Enzyme Inhibitors Biomarkers Blood Glucose Cardiovascular Agents Coronary Artery Disease Cross-Sectional Studies Diabetes Mellitus Europe Female Glycated Hemoglobin A Guideline Adherence Health Care Surveys Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypoglycemic Agents Incidence Male Middle Aged Platelet Aggregation Inhibitors Practice Guidelines as Topic Practice Patterns, Physicians' Treatment Outcome Young Adult EUROASPIRE Study Group Hemoglobin A, Glycosylated |
Publication Status: | Published |
Appears in Collections: | National Heart and Lung Institute |